Prospects for the Use of Antibodies Against Parkinson’s Disease: A Multi-Edged Sword?
Monoclonal antibodies (mAbs) show great potential for targeting α-synuclein aggregates in Parkinson’s disease. However, overcoming barriers like blood-brain barrier penetration, the need for precise target elimination, and reliable early diagnosis remain critical challenges. New approaches, such as engineered nanobodies and advanced drug delivery systems, are being developed to address these obstacles, offering promising pathways for more effective treatments and diagnostics.
Forfatter
Daniel E. Otzen
Professor of Nanobiotechnology, Interdisciplinary Nanoscience Center (iNANO) & Department of Molecular Biology and Genetics, Aarhus University, Denmark
Forfatter
Nikos Hatzakis
Professor, Department of Chemistry & Nano-Science Center, University of Copenhagen, Denmark
Forfatter
Céline Galvagnion
Associate Professor, Department of Drug Design and Pharmacology, University of Copenhagen, Denmark
Forfatter
Krzysztof Kucharz
Associate Professor, Department of Neuroscience, University of Copenhagen, Denmark
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
